Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03399084 · ClinicalTrials.gov registry record · Phase 1

A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia

A Phase 1 study of Iron Deficiency Anemia, sponsored by Sandoz.

Completed
Registry status
Phase 1
Development phase
71
Enrollment target
1
Study location

NCT03399084 is a Phase 1 study of Iron Deficiency Anemia that has completed, run by Sandoz. The registered enrollment target is 71 participants, below the 191-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03399084, a Phase 1 study of Iron Deficiency Anemia, has completed, sponsored by Sandoz.

COMPLETED
Registry status
Phase 1
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.

Conditions Studied

Interventions

  • DRUG Ferric carboxymaltose

Study Locations (1)

Florida

  • Sandoz Investigative Site - Miami

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2017-11-29
Est. Completion 2019-01-15
Phase Phase 1

Sponsor

Sandoz

29 total trials

What the Registry Record Tells You About NCT03399084

The ClinicalTrials.gov registry entry for NCT03399084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (63% lower). The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 1 intervention - of which Ferric carboxymaltose is the first listed.

NCT03399084 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03399084 about?

NCT03399084 is a clinical study titled "A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia". This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.

What is the current status of trial NCT03399084?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2017-11-29. Estimated completion is 2019-01-15.

What conditions does trial NCT03399084 study?

This clinical trial studies the following conditions: Iron Deficiency Anemia.

What interventions are being tested in trial NCT03399084?

The interventions under investigation include: Ferric carboxymaltose (DRUG).

Who is sponsoring clinical trial NCT03399084?

This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03399084 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Iron Deficiency Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.